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INTRODUCTION
Each year, an estimated 50,000 people worldwide will become
afflicted with amyloidosis, with more than 3,000 people receiving
the diagnosis in North America alone. Its symptoms are vague and
nonspecific, often mimicking those of other common conditions.
Amyloidoses are a group of disorders in which soluble proteins
aggregate and get deposited extracellularly in tissues as insoluble
fibrils, causing progressive organ dysfunction (1, 2). More than 20
proteins are known to form amyloid fibrils (3, 4). The two most
common causes of systemic amyloid deposition are monoclonal
immunoglobulin light chains (ALs) and the acute-phase reactant
serum amyloid A (AA). AL amyloidosis is associated with plasma
cell dyscrasias, including monoclonal gammopathy of undeter-
mined significance, and multiple myeloma. AA amyloidosis is typi-
cally secondary to chronic inflammatory conditions, such as rheu-
matoid arthritis and several other inflammatory diseases. Kidneys
are some of the most frequent sites of amyloid deposition in AL, AA,
and several hereditary amyloidoses (5).
The diagnosis of renal amyloidosis on kidney biopsies relies on
Congo red staining, leading to typical apple-green birefringence
under polarized light (5). Once, the potassium permanganate
method with Congo red staining, as described by Wright et al. in
1977 (6), had been widely used to discriminate AL and AA amyloi-
doses. Unfortunately, this method has largely lost the credibility
because of false positive results (7). It was recently recommended to
use immunohistochemical analysis to detect λ - light chain, κ - light
chain and amyloid A for differential diagnosis of AL and AA amyloi-
doses (8). Nonetheless, this immunohistochemical examination
takes a long time and has a problem with reproducibility due to
variations in the protocols and conditions of the antibodies. There-
fore, simple and reproducible methods are needed to distinguish
AL and AA amyloidoses.
In our previous immunofluorescence staining technique for the
detection of a set of immunoglobulins and complements factors for
diagnosis of 130 renal biopsy samples at Tokushima University
Hospital between 2008 and 2010, we performed staining with 4,6 -
diamidino-2-phenylindole (DAPI) for the detection of nuclei in all
samples. In the series of staining of 130 kidney slices, we found that
DAPI produces positive staining in the areas of the extracellular
matrix and cytoplasm only in tissue slices from patients with renal
amyloidosis, and that the DAPI-positive areas reliably coincide
with Congo red-positive areas. In the present study, we investi-
gated the utility of staining with DAPI for the diagnosis of renal
amyloidosis. This study suggests that a staining method involving
the broadly used dye DAPI may serve as a simple and reproducible
diagnostic test for renal amyloidosis.
METHODS
PatientsWe investigated 14 cases of glomerular amyloid deposi-
tion at Tokushima University Hospital and Kawashima Hospital be-
tween 2002 and 2015. Renal amyloidosis were proven by renal bi-
opsy. All of the procedures were performed in accordance with the
guidelines of the Helsinki Declaration on Human Experimentation
and the Ethical Guidelines on Clinical Research published by the
Japanese Health, Labour and Welfare Ministry. This study was ap-
proved by the Ethics Committee of Tokushima University and
Kawashima Hospital, and informed consent was obtained from all
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patients.
Laboratory examination

Ccreatinine in serum was measured
by a enzymatic method. Twenty four-hour urine protein in g/day
was determined to multiply the 24-hour urine volume by the urine
protein concentration measured using a pyrocatechol violet molyb-
date dye-binding method. Serum amyloid A protein (SAA) was
measured by a latex agglutination immunoassay method.
Histology

Histopathological studies were performed on human
tissues. Kidney specimens (n=14) were obtained from renal biop-
sies. Kidney tissue blocks for light microscopy examination were
fixed with Dubosq-Brazil’s solution and embedded in paraffin.
Amyloid staining was performed with Congo-red, exhibited apple-
green birefringence on polarizing microscopy, and confirmed the
reaction of the potassium permanganate digestion.
Immunohistochemistry

Kidney sections were processed for im-
munohistochemistry following standard procedures. Dubosq-
Brazil’s solution- fixed and paraffin-embedded kidney tissue blocks
were used. Before dyeing them, tissue sections (2 µm) were rehy-
drated and treated with HistoVT One (Nacalai Tesque Inc., Kyoto
Japan) for 20 min at 98. To perform DAPI-λ/κ double staining,
sections were stained with FITC-conjugated anti -human lambda
light chains antibody (1 : 40 dilution) (Dako, Kyoto, Japan) or anti -
human kappa light chains antibody (1 : 40 dilution) (Dako, Kyoto,
Japan) for 120 min at room temperature and then incubated with
DAPI (1 : 1000 dilution) (Wako, Osaka, Japan) for 30 min at room
temperature. To perform DAPI-amyloid A double staining, sec-
tions were stained with anti -human amyloid A antibody (1 : 100
dilution) (Dako, Kyoto, Japan) for 90 min at room temperature
followed by incubation with the appropriate secondary antibodies
conjugated with FITC, and then stained with DAPI (1 : 1000 dilu-
tion) for 30 min at room temperature. To perform DAPI-Propidium
lodide double staining, sections were stained with DAPI (1 : 1000
dilution) overnight at 4 and then stained with Propidium lodide
(1 : 500 dilution) (KPL, MD, USA) for 5 min at room temperature.
RESULTS
In an attempt to clarify the differential diagnosis of amyloidosis,
we conducted histochemical evaluation of amyloid deposition in
kidneys. The clinical profile of 14 patients is shown in Table 1. The
presence of λ - light chain monoclonal proteins in serum and/or
urine was examined by immunoelectrophoresis tests. As a result, λ
light chain monoclonal proteins were detected in patients 1

5, 7, 8,
and 10. As for patient 6, these tests were not performed because of
sudden death. Monoclonal proteins were not detected by these
tests in the patient 9. Patients with rheumatoid arthritis (11 to 14)
showed high levels of serum amyloid A. Patients 11 and 14 had
advanced renal failure.
The pathological profile of the patients is shown in Table 2. All
patients had Congo red-positive staining in glomeruli and showed
apple-green birefringence under polarized light. In addition, elec-
tron microscopic analysis revealed amyloid fibrils in glomeruli in
all patients. According to the potassium permanganate method
with Congo red staining, kidney slices from patients 1

9 and 10

14
were potassium permanganate-resistant and potassium perman-
ganate-sensitive, respectively. Patients 11

14 had deposition of
amyloid A in glomeruli. In patient 3, positive staining of λ - light
chain in glomeruli was detected in addition to amyloidA. In patient
10, all staining yield negative results. By bone marrow biopsy,
multiple myeloma was ruled out for patients 1

10. As for patient 6,
the bone marrow biopsy was not performed due to sudden death.
Patient 3 did not have any chronic inflammatory conditions to cause
AA amyloidosis. Although patient 10 received a diagnosis of mono-
clonal gammopathy of undetermined significance, which was close
to AL amyloidosis, the deposition of paraproteins in glomeruli
could not be detected by immunohistochemical and mass spectro-
metric analyses.
The results of DAPI staining in these patients are shown in
Table 3. Glomerular DAPI-positive areas as accompanied with
nuclei were observed in AL amyloidosis, indicating that DAPI-
positive staining areas except for nuclei are consistent with amyloid
deposition areas (Fig. 1g, h). In contrast, the consistency of overlap-
ping staining patterns was not seen in AA amyloidosis (Fig. 1c, f, i).
The overlapping staining patterns with amyloid deposition were
not observed with the staining by means of another nuclear staining
Table 1. The clinical profiles of 14 patients
Patient Age(years)
Sex
Proteinuria
(g/day)
Cr
(mg/dl)
Immunoelectrophoresis SAA
(µg/ml)
Underlying
disease(Blood) (Urine)
1 69M 7.3 1.01 neg BJP-λ N/P
2 76M 4.8 1.61 IgG-λ IgG-λ N/P
3 39F 2.5 0.61 neg BJP-λ N/P
4 55M 3.9 1.68 IgA-λ IgA-λ N/P
5 83M 5.2 0.83 IgG-λ IgG-λ N/P
6 77F 3.1 0.70 N/P N/P N/P
7 81F 2.2 1.05 IgG-λ BJP-λ N/P
8 83M 4.2 0.98 neg BJP-λ N/P
9 62M 2.9 1.05 neg neg N/P
10 67F 1.1 0.76 IgG-λ neg N/P
11 50F 3.7 4.37 N/P N/P 276 RA
12 69F 1.9 1.59 neg neg 61.7 RA
13 67F 6.0 0.64 N/P N/P 714.9 RA
14 34F 6.5 2.34 N/P neg 882 RA
M : male ; F : female ; Cr : serumcreatinine ; neg : negativeresult
N/P : notperformed ; SAA : serumamyloidAprotein ; RA : rheumatoidarthritis
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reagent propidium iodide (PI).
Thus, DAPI-PI double staining was performed on 13 patients ;
DAPI and λ - or κ - light chain double staining was conducted on five
patients with AL amyloidosis ; and DAPI-amyloid A double stain-
ing, on two patients with AA amyloidosis. Consequently, DAPI-
positive areas without nuclei corresponded to the deposition of
paraprotein, which was the λ - light chain monoclonal protein in
every patient with AL amyloidosis(Fig. 2a-c).
DISCUSSION
Amyloidosis is defined as pathological accumulation of extra-
cellular proteins that adopt a β -pleated configuration and share
histochemical characteristics and fibrillary ultrastructure. These
proteins are resistant to degradation. These substances share mor-
phological, ultrastructural, and staining features, but they have dif-
ferent chemical structure. The diagnosis of amyloidosis requires
histological demonstration of amyloid deposits. Many pathologists
Table 2. The pathological profiles of 14 patients
Patient Congo-red Potassium
permanganate
method
Glomerular
λ/κ
lightchain
Glomerular
amyloidA
Glomerular
amyloid fibrils
(Electron microscopy)
1 pos r pos/neg neg 
2 pos r pos/neg neg N/P
3 pos r pos/neg pos 
4 pos r pos/neg neg N/P
5 pos r pos/neg neg 
6 pos r pos/neg neg 
7 pos r pos/neg neg 
8 pos r pos/neg neg 
9 pos r pos/neg neg 
10 pos s neg/neg neg 
11 pos s neg/neg pos 
12 pos s neg/neg pos 
13 pos s neg/neg pos N/P
14 pos s neg/neg pos N/P
pos : positive result ; neg : negative result ; s : sensitive ; r : resistant
+ : present ; - : absent ; N/P : not performed
Figure 1 Microscopic appearance of the glomeruli with deposition of
amyloid. (a -c) Congo-red staining. (d- f) DAPI staining. (g- i) Double
staining of DAPI (blue) and Propidium Iodide (PI) (red). In the glomeruli,
amyloid deposits are present in the mesangial matrix (asterisks) and
along the glomerular basement membrane (arrows). (a, d, g) Patient 1 ;
AL amyloidosis with deposition in mesangiocapillary pattern. (b, e, h)
Patient 7 ; AL amyloidosis with deposition in perimembranous pattern.
(c, f, i) Patient 11 ; AA amyloidosis. Original magnification for all panels
was×400.
Table 3.
Patient Diagnosis DAPI-positive areas
without nuclei
1 AL 
2 AL 
3 AL 
4 AL 
5 AL 
6 AL 
7 AL 
8 AL 
9 AL 
10 MGUS partially present
11 AA 
12 AA 
13 AA 
14 AA 
AL : AL amyloidosis ; AA : AA amyloidosis
MGUS : monoclonal gammopathy of undetermined significance
+ : present ; - : absent
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use Congo red to make a diagnosis of amyloidosis and state the
common opinion that Congo red-stained amyloid in polarized light
shows apple-green birefringence, sometimes called apple-green
dichroism.
Patients with primary amyloidosis can be classified into two
groups : one with potassium permanganate-sensitive and one with
potassium permanganate-resistant amyloid deposits. These two
groups correlate with the clinical classification of typical organ distri-
bution (presenting with nephropathy) and atypical organ distribution
(presenting with cardiomyopathy, nephropathy, and glossopathy)
and the expected presence of amyloid AA or amyloid AL. This histo-
chemical method for differentiating amyloid AA from AL was intro-
duced by Wright et al. (6). The method is based on the affinity of
amyloid for Congo red dye after exposure to potassium permanga-
nate and dilute sulfuric acid. Because potassium permanganate
Congo red staining has been barely used after 2001 (7), it was
recently recommended to use immunohistochemical analysis to
detect λ - light chain, κ - light chain, and amyloid A as a diagnostic
tool for the discrimination of AL and AA amyloidoses (8). On the
other hand, this immunohistochemical examination takes a long
time and has a problem with reproducibility due to variations in the
protocols and conditions of antibodies. Therefore, simple and re-
producible methods are needed to distinguish AL and AA amyloi-
doses.
Our study revealed that extracellular and cytoplasmic glomerular
DAPI-positive areas without nuclei are clearly consistent with amy-
loid deposition in AL amyloidosis. In contrast, the overlapping
staining was not seen in AA amyloidosis. These results suggest that
DAPI-staining can be a useful way to discriminate AL and AA
amyloidoses. It is also well known that glomerular amyloid deposi-
tion is categolized into several types : 1) a mesangiocapillary type
with diffuse amyloid deposition in the mesangium and along both
sides of the glomerular basement membrane ; 2) a perimembra-
nous type principally involving the subepithelial side of the base-
ment membrane ; 3) a mesangial nodular type showing nodular
mesangial deposits ; 4) and a hilar type showing amyloid deposits
in hilar arterioles (9-11). We demonstrated here that DAPI-PI
double staining clarifies the difference in amyloid deposition
types more effectively. Moreover, considering the result of patient
10, DAPI might detect tiny amount of amyloid deposition that is
resistant to the potassium permanganate method, the immuno-
histochemical method, and the mass spectrometry. DAPI (4’,6 -
diamidino-2-phenylindole) is a blue fluorescent nuclear stain broadly
used in fluorescence microscopy assays (12). It is known that DAPI
binds to some kind of protein (13-15). Recently, many molecular
probes for amyloid fibrils have been reported (16, 17). Some 2-
phenylindole derivatives are known as such probes (18), but as
far as we know, there are no reports that DAPI can be used as a
diagnostic dye for renal amyloidosis. Although the molecular
binding mechanism is unknown in detail, the following is one
possibility. It is known that AA-amyloid protein has a higher pro-
portion of arginine than AL-amyloid protein does (6, 19, 20). Be-
cause DAPI and arginine both have basic pKa, they carry a positive
charge and repel each other under physiological conditions. This
may be one of the reasons why DAPI does not bind to AA amyloid
protein.
In conclusion, we demonstrated here that widely used DAPI
staining is more rapid and easier to perform than the potassium
permanganate method with Congo red staining and the immuno-
histochemistry to detect amyloid paraprotein. DAPI can detect
even a small deposit of amyloid paraprotein for testing of resis-
tance to the potassium permanganate method and to immunohisto-
chemical analysis. Moreover, DAPI staining revealed these deposits
more clearly than Congo red staining did in most patients in this
study. These results suggested that the staining method with
popular dye DAPI may be rapid and easy way to discriminate AL
and AA amyloidoses. It is imperative for clinicians and patholo-
gists to consider amyloidosis as part of their differential diagnosis.
Given the simple and reproducible staining method for amyloid
proteins, testing for the disease becomes easier too. Early accurate
diagnosis is necessary for patients with amyloidosis, and they may
benefit from the new diagnostic procedure that is available to im-
prove and extend life. We cannot deny that this study only shows a
preliminary result because there were only a limited number of
such patients available at our institution. Nonetheless, we believe
that this result represents an interesting finding, and that confirma-
tion on a large sample size should make this conclusion firmer.
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Figure 2 Cytoplasmic staining with DAPI is coincided with the deposition of λ light chain. (a) Immunofluorescence stainings for λ light
chain. (b) DAPI staining. (c) Overlay images of DAPI (blue) and λ light chain (green). (a-c) Patient 1 ; AL amyloidosis with deposition in
mesangiocapillary pattern. Original magnification for all panels was ×400.
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